AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
Stock Information for AIM ImmunoTech Inc.
Loading
Please wait while we load your information from QuoteMedia.